2 reports of this reaction
3.4% of all BEVACIZUMAB TNJN reports
#10 most reported adverse reaction
VOMITING is the #10 most commonly reported adverse reaction for BEVACIZUMAB TNJN, manufactured by Bio-Thera Solutions, Ltd.. There are 2 FDA adverse event reports linking BEVACIZUMAB TNJN to VOMITING. This represents approximately 3.4% of all 59 adverse event reports for this drug.
Patients taking BEVACIZUMAB TNJN who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is moderately reported among BEVACIZUMAB TNJN users, representing a notable but not dominant share of adverse events.
In addition to vomiting, the following adverse reactions have been reported for BEVACIZUMAB TNJN:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 2 FDA reports for BEVACIZUMAB TNJN. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 3.4% of all adverse event reports for BEVACIZUMAB TNJN, making it a notable side effect.
If you experience vomiting while taking BEVACIZUMAB TNJN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.